Pharmaceutical Technology
UCB’s Candid acquisition marks its second foray into the TCE space – closely following a $1.1bn licensing deal with TCE specialist, Antengene.
Pharmaceutical Technology
UCB's Candid acquisition marks its second foray into the TCE space - closely following a $1.1bn licensing deal with TCE specialist, Antengene.
Pharmaceutical Technology
UCB’s Candid acquisition marks its second foray into the TCE space – closely following a $1.1bn licensing deal with TCE specialist, Antengene.